Neuronetics Q3 Margin Gains Fail to Resolve Covenant Overhang

What happened

Neuronetics reported Q3 2026 revenue of $41.96 million, with Greenbrook clinic revenue growing 18% and total gross margin expanding to 52.2%, leading to positive operating income of $0.54 million and adjusted EBITDA of $1.9 million. Despite these improvements, the company still posted a net loss of $1.56 million and management reiterated substantial doubt about its ability to continue as a going concern due to projected breach of the March 31, 2027 revenue covenant. Cash and equivalents stood at just $22.1 million against $65 million in Perceptive borrowings, while the share count rose to 76.2 million after continued ATM issuance. The operating progress confirms better cost control and clinic execution, but it does not eliminate the need for covenant relief or additional financing. Investors should treat this press release as confirmation of the known operating trajectory, not as a resolution of the capital structure risk.

Implication

The Q3 beat on margins and EBITDA demonstrates that management can execute on integration, but the financing overhang remains the dominant driver of equity value. Until the March 2027 covenant is waived or amended, any upside is capped by the risk of coercive dilution or lender action. The company's reliance on ATM sales signals continued cash needs and further per-share erosion, making the current share price unattractive relative to the base-case implied value of $2.20. Investors should monitor Q4 results for evidence of a compliance path or lender accommodation, and also track AdvancedMD adoption as a potential demand catalyst. A more attractive entry closer to $1.70 would provide a margin of safety, but only if the financing risk is not resolved in the interim.

Thesis delta

The Q3 results are consistent with the master report's base case and do not change the 'POTENTIAL SELL' rating. Operating improvements strengthen the bull scenario but do not alter the probability distribution because the March 31, 2027 covenant risk remains unresolved. The thesis continues to require all three of clinic growth, NeuroStar reacceleration, and covenant relief with limited dilution; only the first is currently evidenced.